PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.07%
Both companies show declining cash positions (-1.07% vs TRVN's -17.75%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half of TRVN's -17.75%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half of TRVN's -18.28%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half of TRVN's -16.37%. Michael Burry sees a potential red flag for stagnation or capital shortage.
29.45%
Less than half of TRVN's -18.90%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.08%
1.1-1.25x TRVN's 16.90%. Bill Ackman questions if the firm is taking on more near-term obligations than competitor.
6.41%
Less than half of TRVN's -100.00%. David Dodd sees more deleveraging vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.41%
Less than half of TRVN's -0.77%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
11.06%
Above 1.5x TRVN's 1.42%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.15%
≥ 1.5x TRVN's -0.82%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
382.94%
Higher Other Stockholders' Equity Items Growth compared to TRVN's zero value, indicating worse performance.
-11.47%
Below half TRVN's -22.96%. Michael Burry sees potential underperformance in building shareholder capital.
-1.07%
Below half TRVN's -16.37%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
6.41%
Less than half of TRVN's -94.51%. David Dodd sees less overall debt expansion vs. competitor.
6.78%
Less than half of TRVN's -156.99%. David Dodd sees better deleveraging or stronger cash buildup than competitor.